Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of trastuzumab rezetecan (SHR-A1811) in HER2-abnormal solid tumors
ChiCTR2600133591Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab rezetecan in Nonhematologic neoplasms, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: real-world objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600133591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133591.